July 2024
Leading generics pharmaceutical company Krka is celebrating its 70th anniversary since it launched its first human pharmaceuticals laboratory and over 50 years supporting animal health. This milestone year is also marked by the company’s first Environmental, Social and Governance (ESG) rating being awarded at the end of 2023, placing it in the top 10 percent of pharmaceutical companies accredited by S&P Global, a world-leading ESG rating auditor1.
The rating success reflects Krka’s ever-increasing focus on sustainability from the early 2000’s with initiatives implemented since 2018 resulting in over 50 million euros being invested in environmental protection. The company continues its strategic plan to further reduce its carbon footprint, with key targets set for 2025, 2030 and 2050.
As Charlotte Read, Krka UK Sales Manager highlights, “Krka has grown significantly in recent years and we are immensely proud that our reputation for being sustainable and ethical remains steadfast. Since 2019 we have recorded a 48 percent decrease in CO2 emissions which just shows that a lot can still be achieved by our wider environmental and social responsibilities being integral to the company’s day to day operations. As we entered our 70th birthday year, a top ESG rating was the icing on the cake and we were delighted to celebrate this achievement at the BVA Live event in June.”
Since its inception in 1954 Krka has focussed on production quality and efficiency and this approach has also driven positive impacts for environmental protection. Of particular note is the benefit of Krka’s manufacturing system which, as a complete end-to-end process from the active pharmaceutical ingredient (API) to final product, brings not only benefits to quality control and operational efficiency, but also optimises product miles to reduce carbon footprint.
This year has also offered customer teams and event delegates the opportunity to engage with Krka’s new UK Veterinary Technical Adviser, Renzo Di Florio. As Krka embarks on its next chapter, Renzo reaffirmed the company’s commitment to innovation in animal health, saying, “Our state-of-the-art production facilities enable us to embed palatability throughout our tablet design, helping to improve compliance and treatment outcomes. This is just one example of how Krka combines cutting-edge technology with a clear understanding of veterinary needs, ensuring we continue to provide high quality, effective, sustainable solutions for the profession, long into the future.”
Find out more on Krka’s ESG policy here.
Press contact: Katy Ellison, katy@companionconsultancy.com, Tel 07596 217372.
References:
- https://www.krka.biz/about-us/sustainability/krka-esg-rating/ Krka ranked among the top 10% in the pharmaceutical industry for S&P Global accredited companies, based on Krka CSA Score of 24 November 2023.
About Krka
Krka is one of the leading generic pharmaceutical companies in the world and our medicines are used to treat more than 100 million patients worldwide. With over 50 years in developing animal health solutions Krka continues to bring innovation to the category with its branded generics.
Working closely with customers, Krka supplies licensed medicines that deliver effective and consistent performance in clinical practice. Krka’s animal health portfolio provides high efficacy pharmaceuticals for both companion and food producing animals. Key brands include Tolracol® for coccidiosis management in cows and sheep, and Milprazon CHEWABLE® a comprehensive worming solution for dogs and cats. The latest additions to our companion animal range include, Robexera® for targeted pain management and Cladaxxa® for infection control.
Leave a Reply